Methods of treating myeloproliferative disorders
US12070464B2 · kind B2 · utility
0Cited by
2References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 1, 2022 |
| Grant date | Aug 27, 2024 |
| Priority date | — |
| Expiry date | Apr 12, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to the use of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, and pharmaceutically acceptable salts thereof, for treating myelofibrosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.